Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Sana Biotechnology, Inc. (NASDAQ:SANA) has received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $8.1429.

Several analysts recently issued reports on SANA shares. Bank of America increased their price objective on Sana Biotechnology from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. JMP Securities set a $8.00 price target on Sana Biotechnology in a research note on Thursday, October 30th. HC Wainwright lowered their price target on Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Wall Street Zen upgraded Sana Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Finally, Citizens Jmp lifted their target price on shares of Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a research note on Thursday, October 30th.

Sana Biotechnology Stock Performance

SANA stock opened at $4.74 on Thursday. The firm has a 50 day simple moving average of $4.29 and a 200 day simple moving average of $4.06. Sana Biotechnology has a 52 week low of $1.26 and a 52 week high of $6.55. The stock has a market cap of $1.26 billion, a P/E ratio of -4.89 and a beta of 1.96.

Sana Biotechnology (NASDAQ:SANA) last released its earnings results on Thursday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. Sell-side analysts predict that Sana Biotechnology will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Sana Biotechnology

Several hedge funds have recently bought and sold shares of the business. Foguth Wealth Management LLC. acquired a new stake in shares of Sana Biotechnology in the fourth quarter worth about $44,000. JPMorgan Chase & Co. lifted its stake in shares of Sana Biotechnology by 180.8% in the third quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock worth $7,581,000 after buying an additional 1,375,029 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new stake in shares of Sana Biotechnology in the third quarter worth $50,000. Ovata Capital Management Ltd bought a new stake in shares of Sana Biotechnology during the 3rd quarter worth $355,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Sana Biotechnology in the 3rd quarter valued at $215,000. 88.23% of the stock is owned by institutional investors and hedge funds.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.